Details for Patent: 9,095,509

Which drugs does patent 9,095,509 protect, and when does it expire?

Patent 9,095,509 protects RENVELA and is included in one NDA.

This patent has thirty patent family members in eighteen countries.

Summary for Patent: 9,095,509

Title:	Sachet formulation for amine polymers
Abstract:	A powder formulation comprises a pharmaceutically acceptable anionic stabilizer and an aliphatic amine polymer or a pharmaceutically acceptable salt thereof mixed with the anionic stabilizer. The powder formulation is conveniently packaged in a container, such as a sachet. A method of treating a subject with hyperphosphotemia with the powder formulation is also disclosed.
Inventor(s):	Bhagat; Hitesh R. (Wayland, MA), Goldberg; Jeffrey M. (Framingham, MA)
Assignee:	Genzyme Corporation (Cambridge, MA)
Application Number:	11/519,982
Patent Claim Types: see list of patent claims	Compound;

Drugs Protected by US Patent 9,095,509

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-002	Feb 18, 2009	AB	RX	Yes	Yes			Y
Genzyme	RENVELA	sevelamer carbonate	FOR SUSPENSION;ORAL	022318-001	Aug 12, 2009	AB	RX	Yes	No			Y

International Family Members for US Patent 9,095,509

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006292672
Brazil	PI0616078
Canada	2622693
China	101272762
China	103027896